AptarGroup
ATR
140.08
-0.26
-0.19%
AptarGroup
US · ATR
#1713 by market cap
Listed 1970
140.08
-0.26
-0.19%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Company notice
Astron Corp Ltd (Delisted): Application for quotation of securities - ATRASX · 2026/4/1
-
Rating change
Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $145Market Newswire · 2026/6/12
-
Company notice
Astron Corp Ltd (Delisted): Application for quotation of securities - ATRASX · 2026/6/2
-
Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin ModelsPR Newswire · 2026/11/10
-
BofA Securities Maintains AptarGroup(ATR.US) With Buy RatingMarket Newswire · 2026/10/31
-
UBS Maintains AptarGroup(ATR.US) With Hold Rating, Raises Target Price to $142Market Newswire · 2026/11/3
-
Company notice
AI: Statutory ex post facto disclosure documents (merger) (ATR-Trek Co., Ltd.)JPX · 2025/9/1
-
Rating change
Raymond James Maintains AptarGroup(ATR.US) With Buy Rating, Cuts Target Price to $160Market Newswire · 2026/7/15
-
Rating change
BofA Securities Upgrades AptarGroup(ATR.US) to Buy Rating, Raises Target Price to $173Market Newswire · 2026/7/14
-
Rating change
BofA Securities Maintains AptarGroup(ATR.US) With Buy Rating, Cuts Target Price to $154Market Newswire · 2026/10/6
-
Rating change
Analysts' Opinions Are Mixed on These Healthcare Stocks: AptarGroup (ATR) and Contineum Therapeutics, Inc. Class A (CTNM)TipRanks · 2026/7/31
-
Company notice
Astron Corp Ltd (Delisted): Application for quotation of securities - ATRASX · 2026/5/18
-
Rating change
Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $155Market Newswire · 2026/10/19
-
Company notice
AI: Statutory Advance Disclosure Documents (merger) (ATR-Trek Co., Ltd.)JPX · 2025/7/22
-
BofA Securities Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $155Market Newswire · 2026/11/2
-
Rating change
Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Raises Target Price to $155Market Newswire · 2026/8/3
-
Rating change
BofA Securities Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $172Market Newswire · 2026/8/21
-
Rating change
Deutsche Bank Initiates AptarGroup(ATR.US) With Buy Rating, Announces Target Price $150Market Newswire · 2026/10/7
-
UBS Initiates AptarGroup(ATR.US) With Hold Rating, Announces Target Price $135Market Newswire · 2026/10/9
-
Rating change
William Blair Maintains AptarGroup(ATR.US) With Hold RatingMarket Newswire · 2026/7/31
-
Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients With Rashes Due to KRAS and MEK InhibitorsPR Newswire · 2026/10/29
-
Rating change
Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Raises Target Price to $145Market Newswire · 2026/5/4
-
Earnings Flash (ATR) AptarGroup, Inc. Posts Q3 Adjusted EPS $1.52 per Share, Vs. FactSet Est of $1.47MT Newswires · 2026/10/30
-
Rating change
DBS Maintains AptarGroup(ATR.US) With Buy Rating, Cuts Target Price to $170Market Newswire · 2026/3/19
-
Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $155Market Newswire · 2026/10/8
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
AptarGroup discussion 0 comments